ClinicalTrials.gg
CompletedNCT07388992GAIT-MSUpdated Nov 17, 2026

Investigating Specific Gait Patterns in Individuals Living With Multiple Sclerosis

An observational study in Multiple Sclerosis and Healthy Adult, sponsored by SYSNAV. Completed at 1 site in France. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by SYSNAV · Observational

How we know

Updated Nov 17, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
30
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 376 studies in Multiple Sclerosis with a site in France — 63 open to participants now, 92 under way, 18 of them phase 3. Multiple Sclerosis · France.

Enrollment
122nd of 132
30 · median 174
Started
2026
with 12 others
Observational
132 of 376
21 open now
Registered
368th of 376
by date

Among the 376 studies in Multiple Sclerosis with a site in France, this one is the 122nd largest by enrollment of the 132 observational ones that give a count, is one of 13 that started in 2026, is one of 132 observational ones, and was the 368th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

63 of the 376 studies in Multiple Sclerosis with a site in France are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 376 studies in Multiple Sclerosis with a site in France, or all of them as a file.
02

Study summary

The study aims to investigate specific ambulation patterns characteristic of the quality of gait in people with MS (pwMS)

03

Conditions studied

  • Multiple Sclerosis
  • Healthy Adult

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with MS will be recruited from the CHU Lille. Patients will be informed of this study by the Investigator during routine follow-up visits.

The Investigator will also connect with local patient organizations and share a flyer. This flyer will also be displayed within the Neurology and Neurological Rehabilitation departments of the hospital and diffused to the hospital staff.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For people living with multiple sclerosis (pwMS):

  1. Age at inclusion between =18 and =65 years old
  2. Signed and ability to comply with study and follow-up.
  3. Confirmed MS diagnosis according to McDonald criteria (2017)
  4. Expanded Disability Status Scale EDSS = 6
  5. Stable treatment for 2 months before inclusion (for both disease modifying and symptomatic therapies)
  6. Ability and willingness to participate in and comply with all study procedures defined in the protocol
  7. Subject will be eligible for enrollment in this study only if either affiliated to, or a beneficiary of a social security category

For Healthy volunteers :

  1. Age at inclusion between =18 and =65 years old
  2. Signed informed consent and ability to comply with study and follow-up.
  3. Ability and willingness to participate in and comply with all study procedures defined in the protocol
  4. Subject will be eligible for enrollment in this study only if either affiliated to, or a beneficiary of a social security category

Exclusion criteria

Exclusion Criteria:

For pwMS:

  1. Participants with a relapse within the past 3 months before the inclusion
  2. Participants with significant cognitive disorders, limiting the understanding of the exercises to be performed or presence of apparent communication difficulties hindering the correct collection of data, as assessed by the investigator
  3. Past or present pathology other than MS or surgery or trauma impacting gait, ambulatory function or upper limb function, as assessed by the investigator
  4. Vulnerable adults: individuals subject to a legal protection measure (guardianship, limited guardianship, or judicial protection) or unable to express their consent.

For healthy volunteers (HV):

  1. Participants with significant cognitive disorders, limiting the understanding of the exercises to be performed or presence of apparent communication difficulties hindering the correct collection of data, as assessed by the investigator
  2. Past or present pathology or surgery or trauma impacting gait, ambulatory function or upper limb function, as assessed by the investigator
  3. Vulnerable adults: individuals subject to a legal protection measure (guardianship, limited guardianship, or judicial protection) or unable to express their consent.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
30 participants (actual)
Patient registry
No

Groups and cohorts

  • people living with Multiple Sclerosis
  • Healthy Adult
06

What researchers measure

Primary outcomes

  1. description of ambulation pattern in controlled environment in people living with multiple sclerosis (pwMS) with different disease severities

    Measurement of daily life-like activity movements by Optical Motion Capture, pressure sensitive walkway and wearable sensors

    Time frame: enrollment

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2026 to primary completion in Apr 2026, 0 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Jun 2026 → Apr 2026 and completion Jun 2026 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Feb 5, 2026
StartActual
Mar 16, 2026
Primary completionActual
Apr 2, 2026was Jun 2026
CompletionActual
Apr 2, 2026was Jun 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 17, 2026
Primary completion
Jun 2026→Apr 2, 2026 (actual)
Nov 17, 2026
Study completion
Jun 2026→Apr 2, 2026 (actual)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Recruiting→Completed
    Primary completion Jun 2026→Apr 2, 2026 (now actual)
    Study completion Jun 2026→Apr 2, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07388992
Lead sponsor
SYSNAV
Responsible party
Sponsor
First posted
Feb 5, 2026
Start date
Mar 16, 2026
Primary completion
Apr 2, 2026
Completion
Apr 2, 2026
Last update
Nov 17, 2026

Study contacts

Patrick Vermersch
principal investigator · CHU Lille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion